Current and emerging treatments for relapsing multiple sclerosis in Argentinian patients: a review

被引：1
|
作者：
Rojas, Juan I. [1 ]
Patrucco, Liliana [1 ]
Cristiano, Edgardo [1 ]
机构：
[1] Hosp Italiano Buenos Aires, Neurol Dept, Multiple Sclerosis Ctr Buenos Aires, Buenos Aires, DF, Argentina
来源：
DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE | 2014年 / 4卷
关键词：
multiple sclerosis; Argentina; treatments; disease-modifying drugs;
D O I：
10.2147/DNND.S46557
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system. Recent developments have led to newer therapeutic options for disease treatment. A few studies have reported MS prevalence rates between 12 and 20 per 100,000 inhabitants nationwide in Argentina, and an incidence of 1.76 cases per 100,000 inhabitants per year. Considering the epidemiology of MS in Argentina, the total number of patients affected is estimated at 5,000-8,000 patients, with nearly 55%-65% of patients having a relapsing-remitting MS subtype of the disease. The aim of this review is to provide an overview of current and emerging treatments available in Argentina for patients with MS.
引用
收藏
页码：103 / 109
页数：7
相关论文
共 50 条
  • [41] A retrospective chart review in patients with relapsing-remitting multiple sclerosis (RRMS)
    Cursiefen, S.
    Kanter, I.
    Niemczyk, G.
    Schicklmaier, P.
    Wernsdoerfer, C.
    Schwab, S.
    Maeurer, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 142 - 142
  • [42] Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis
    McCool, Rachael
    Wilson, Katy
    Arber, Mick
    Fleetwood, Kelly
    Toupin, Sydney
    Thom, Howard
    Bennett, Iain
    Edwards, Susan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 29 : 55 - 61
  • [43] Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis
    Petri Mankinen
    Tuomas Lundström
    Erkki Soini
    Marja-Liisa Sumelahti
    Juhani Ruutiainen
    Ulla Niskala
    Elina Järvinen
    Advances in Therapy, 2020, 37 : 800 - 818
  • [44] Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis
    Mankinen, Petri
    Lundstrom, Tuomas
    Soini, Erkki
    Sumelahti, Marja-Liisa
    Ruutiainen, Juhani
    Niskala, Ulla
    Jarvinen, Elina
    ADVANCES IN THERAPY, 2020, 37 (02) : 800 - 818
  • [45] The effects of immunomodulatory treatments on the progression of relapsing-remitting multiple sclerosis
    Candan, E
    Yilmaz, Z
    Canturk, IA
    Isik, N
    Yildiz, N
    Seleker, T
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S234 - S235
  • [46] Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data
    Hauer, Larissa
    Sellner, Johann
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 3915 - 3927
  • [47] Current and Emerging Therapies for Multiple Sclerosis Preface
    Keegan, B. Mark
    SEMINARS IN NEUROLOGY, 2013, 33 (01) : 3 - 3
  • [48] Current and emerging pharmacological treatments for sarcoidosis: a review
    Beegle, Scott H.
    Barba, Kerry
    Gobunsuy, Romel
    Judson, Marc A.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2013, 7 : 325 - 338
  • [49] Anxiety in Argentinian patients with multiple sclerosis: Prevalence and associated factors
    Chertcoff, Anibal
    Curbelo, Maria Celeste
    Bauer, Johana
    Ferrandina, Flavia
    Martinez, Alejandra
    Steinberg, Judith
    Carra, Adriana
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 41
  • [50] Anxiety in Argentinian patients with multiple sclerosis: prevalence and associated factors
    Chertcoff, A.
    Curbelo, M. C.
    Bauer, J.
    Ferrandina, F.
    Blanco, S.
    Martinez, A.
    Steinberg, J.
    Carra, A.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 831 - 831
12345